Compare · DRNA vs FLXN
DRNA vs FLXN
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA is the larger of the two at $2.96B, about 6.4x FLXN ($458.9M).
- DRNA has more recent analyst coverage (14 ratings vs 7 for FLXN).
- Company
- Dicerna Pharmaceuticals, Inc.
- Flexion Therapeutics, Inc.
- Price
- $38.23+0.61%
- $25.11-0.20%
- Market cap
- $2.96B
- $458.9M
- 1M return
- -
- -0.20%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 7
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)